120 related articles for article (PubMed ID: 8336992)
1. Analgesic effect of the somatostatin analogue octreotide in two acromegalic patients: a double-blind study with long-term follow-up.
Schmidt K; Althoff PH; Harris AG; Prestele H; Schumm-Draeger PM; Usadel KH
Pain; 1993 May; 53(2):223-227. PubMed ID: 8336992
[TBL] [Abstract][Full Text] [Related]
2. Headache in acromegaly: dramatic improvement with the somatostatin analogue SMS 201-995.
Musolino NR; Marino Júnior R; Bronstein MD
Clin J Pain; 1990 Sep; 6(3):243-5. PubMed ID: 2135020
[TBL] [Abstract][Full Text] [Related]
3. [Analgesic effect of Sandostatin (SMS 201-995) in acromegaly headache].
Sicolo N; Martini C; Ferla S; Roggenkamp J; Vettor R; De Palo C; Federspil G
Minerva Endocrinol; 1990; 15(1):37-42. PubMed ID: 2274013
[TBL] [Abstract][Full Text] [Related]
4. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
5. [Long-term treatment of acromegaly with the somatostatin analog octreotide (Sandostatin). On the predictive significance of acute tests].
Schmidt K; Althoff PH; Harris A; Hofmeister-Wagner W; Schifferdecker E; Schöffling K
Med Klin (Munich); 1990 Dec; 85(12):700-6. PubMed ID: 2128367
[TBL] [Abstract][Full Text] [Related]
6. Truncated somatostatin receptor 5 may modulate therapy response to somatostatin analogues--Observations in two patients with acromegaly and severe headache.
Marina D; Burman P; Klose M; Casar-Borota O; Luque RM; Castaño JP; Feldt-Rasmussen U
Growth Horm IGF Res; 2015 Oct; 25(5):262-7. PubMed ID: 26188991
[TBL] [Abstract][Full Text] [Related]
7. Analgesic effect of octreotide in headache associated with acromegaly is not mediated by opioid mechanisms. Case report.
Pascual J; Freijanes J; Berciano J; Pesquera C
Pain; 1991 Dec; 47(3):341-344. PubMed ID: 1664509
[TBL] [Abstract][Full Text] [Related]
8. The analgesic effect and development of dependency to somatostatin analogue (octreotide) in headache associated with acromegaly.
Popovic V; Paunovic VR; Micic D; Nesovic M; Kendereski A; Djordjevic P; Manojlovic D; Micic J
Horm Metab Res; 1988 Apr; 20(4):250-1. PubMed ID: 2899539
[No Abstract] [Full Text] [Related]
9. Sandostatin LAR in acromegalic patients: a dose-range study.
Fløgstad AK; Halse J; Haldorsen T; Lancranjan I; Marbach P; Bruns C; Jervell J
J Clin Endocrinol Metab; 1995 Dec; 80(12):3601-7. PubMed ID: 8530606
[TBL] [Abstract][Full Text] [Related]
10. Octreotide treatment of acromegaly. A randomized, multicenter study.
Ezzat S; Snyder PJ; Young WF; Boyajy LD; Newman C; Klibanski A; Molitch ME; Boyd AE; Sheeler L; Cook DM
Ann Intern Med; 1992 Nov; 117(9):711-8. PubMed ID: 1416572
[TBL] [Abstract][Full Text] [Related]
11. Octreotide as primary therapy for acromegaly.
Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
[TBL] [Abstract][Full Text] [Related]
12. Clinical and biochemical effects of incremental doses of the long-acting somatostatin analogue SMS 201-995 in ten acromegalic patients.
Shi YF; Harris AG; Zhu XF; Deng JY
Clin Endocrinol (Oxf); 1990 Jun; 32(6):695-705. PubMed ID: 2200620
[TBL] [Abstract][Full Text] [Related]
13. A single-dose comparison of the acute effects between the new somatostatin analog SOM230 and octreotide in acromegalic patients.
van der Hoek J; de Herder WW; Feelders RA; van der Lely AJ; Uitterlinden P; Boerlin V; Bruns C; Poon KW; Lewis I; Weckbecker G; Krahnke T; Hofland LJ; Lamberts SW
J Clin Endocrinol Metab; 2004 Feb; 89(2):638-45. PubMed ID: 14764775
[TBL] [Abstract][Full Text] [Related]
14. Slow release lanreotide treatment in acromegalic patients previously normalized by octreotide.
Morange I; De Boisvilliers F; Chanson P; Lucas B; DeWailly D; Catus F; Thomas F; Jaquet P
J Clin Endocrinol Metab; 1994 Jul; 79(1):145-51. PubMed ID: 8027218
[TBL] [Abstract][Full Text] [Related]
15. A long-term dose-response study of somatostatin analogue (SMS 201-995, octreotide) in resistant acromegaly.
McKnight JA; McCance DR; Sheridan B; McIlrath E; Hadden DR; Kennedy L; Atkinson AB
Clin Endocrinol (Oxf); 1991 Feb; 34(2):119-25. PubMed ID: 1902408
[TBL] [Abstract][Full Text] [Related]
16. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly.
Quabbe HJ; Plöckinger U
J Clin Endocrinol Metab; 1989 May; 68(5):873-81. PubMed ID: 2565912
[TBL] [Abstract][Full Text] [Related]
17. [Long acting sandostatine (sandostatine LAR) in the treatment of acromegaly].
Priou A; Levesque G; Simonetta C; Lancranjan I; Roger P; Jaquet P
Ann Endocrinol (Paris); 1995; 56(3):213-8. PubMed ID: 7677407
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of 189 acromegalic patients with the somatostatin analog octreotide. Results of the International Multicenter Acromegaly Study Group.
Vance ML; Harris AG
Arch Intern Med; 1991 Aug; 151(8):1573-8. PubMed ID: 1872661
[TBL] [Abstract][Full Text] [Related]
19. The effect of octreotide treatment on somatic and psychological symptoms of acromegaly.
Ruchala M; Stangierska I; Gurgul E; Stangierski A; Fajfer J; Sowinski J
Neuro Endocrinol Lett; 2010; 31(2):265-9. PubMed ID: 20424578
[TBL] [Abstract][Full Text] [Related]
20. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients.
Lancranjan I; Bruns C; Grass P; Jaquet P; Jervell J; Kendall-Taylor P; Lamberts SW; Marbach P; Orskov H; Pagani G; Sheppard M; Simionescu L
Metabolism; 1996 Aug; 45(8 Suppl 1):67-71. PubMed ID: 8769387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
